GSK denies infringement
June 12, 2013
GLAXOSMITHKLINE is denying
allegations of patent infringement
related to the dosing device for
Children’s Panadol 1-5 years
suspension, saying it’s disappointed
at the interim injunction which
has taken the product off shelves
around the country (PD Fri).
Reckitt Benckiser was successful
in seeking the injunction, claiming
that GSK had copied the Nurofen
for Children dosing system.
GSK has issued a statement
reassuring customers that there’s
no safety issue, and confirmed
work on an “alternative dosing
device” to minimise any disruption
in the availability of the product.
The dosing device comprises
the bottle, the bottle neck liner
and a flat nosed syringe, with
the injunction not affecting
other Panadol products including
children’s Baby Drops, Children’s
5-12 yrs elixir and the new
Children’s 5-12 yrs suspension.
GSK says it “looks forward to
a successful resolution of the
proceedings when all the evidence
becomes available”.
The above article was sent to subscribers in Pharmacy Daily's issue from 12 Jun 13To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Jun 13
